Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Moderate Buy” by Analysts

Posted by George Bondi on Jun 14th, 2026

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Get Free Report) have earned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $56.7143.

Several analysts recently issued reports on IMCR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, April 20th. Jefferies Financial Group cut Immunocore from a “buy” rating to a “hold” rating and cut their target price for the stock from $48.00 to $33.00 in a research report on Monday, March 16th. Zacks Research upgraded Immunocore from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, Needham & Company LLC increased their target price on Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th.

Read Our Latest Stock Report on IMCR

Institutional Trading of Immunocore

Several institutional investors have recently made changes to their positions in IMCR. Millennium Management LLC grew its position in shares of Immunocore by 334.3% during the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock worth $45,993,000 after purchasing an additional 974,463 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Immunocore during the fourth quarter worth about $20,305,000. Janus Henderson Group PLC bought a new position in Immunocore during the fourth quarter valued at approximately $15,734,000. Bellevue Group AG boosted its stake in Immunocore by 14.5% during the third quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after buying an additional 354,973 shares during the last quarter. Finally, Tang Capital Management LLC boosted its stake in Immunocore by 14.0% during the fourth quarter. Tang Capital Management LLC now owns 2,628,538 shares of the company’s stock valued at $91,237,000 after buying an additional 322,930 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

Shares of IMCR opened at $28.96 on Friday. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The business has a 50-day simple moving average of $29.61 and a two-hundred day simple moving average of $32.33. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -52.65 and a beta of 0.74. Immunocore has a 52 week low of $27.56 and a 52 week high of $40.71.

Immunocore (NASDAQ:IMCR – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The business had revenue of $106.68 million during the quarter, compared to analysts’ expectations of $145.20 million. During the same quarter in the prior year, the business posted $0.10 earnings per share. The business’s quarterly revenue was up 13.6% on a year-over-year basis. On average, analysts expect that Immunocore will post 0.06 EPS for the current year.

About Immunocore

(Get Free Report)

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.